Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (NASDAQ: LTRN) generates a steady flow of news as an AI-driven, clinical-stage oncology company advancing both a precision medicine pipeline and a proprietary artificial intelligence platform. News coverage on this page centers on developments in its RADR® AI and machine learning platform, clinical trial milestones for LP-184, LP-284, and LP-300, regulatory interactions, and strategic initiatives that shape the company’s position in AI-enabled cancer drug development.
Investors and researchers following LTRN news will find detailed updates on Phase 1 and Phase 2 clinical trials, including safety and efficacy readouts, biomarker findings, and disease control observations in heavily pre-treated cancer patients. Recent announcements have highlighted LP-184’s Phase 1a results in advanced solid tumors, LP-284’s activity in relapsed or refractory B-cell lymphomas, and LP-300 data from the HARMONIC™ trial in never-smoker non-small cell lung cancer. Lantern also reports on FDA designations such as Fast Track, Orphan Drug, and Rare Pediatric Disease status that influence development pathways for its drug candidates.
In addition to clinical results, Lantern’s news stream covers the evolution of its RADR® platform and related AI modules. Articles describe the launch and performance of tools like predictBBB.ai for blood–brain barrier prediction and LBx-AI for liquid biopsy-based treatment response modeling, as well as presentations at scientific meetings and symposia. Corporate news items include quarterly financial updates, at-the-market financing agreements, board appointments, proxy statements, and the announcement of an AI Center of Excellence in Bengaluru, India to scale RADR® and multi-agent AI systems for global biopharma partners.
By reviewing the LTRN news feed, readers can track how Lantern integrates AI, genomics, and clinical data into its oncology programs, how regulators and collaborators engage with its pipeline, and how the company positions its AI modules and partnerships in the broader biopharmaceutical landscape. This page is a resource for monitoring material events, clinical inflection points, and platform advances that Lantern discloses through press releases and regulatory communications.
Lantern Pharma (NASDAQ: LTRN) announced that President & CEO Panna Sharma will present at the Benzinga Healthcare Small Cap Conference virtually from September 29-30, 2021. Sharma's presentation is scheduled for September 29 at 11:55 AM ET, with one-on-one meetings available throughout the event. Lantern Pharma is focused on oncology drug development, utilizing its proprietary RADR® A.I. platform to identify patients likely to benefit from their genomically targeted therapeutics.
Lantern Pharma (NASDAQ: LTRN) announced participation in two virtual investor conferences in September 2021. Panna Sharma, President & CEO, will host one-on-one meetings at the Colliers Institutional Investor Conference on September 9-10. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with a presentation available on-demand starting September 13 at 7:00 AM ET. Lantern Pharma leverages its RADR® A.I. platform to discover targeted therapies for oncology, complimented by four drug candidates in development.
Lantern Pharma (NASDAQ: LTRN) announced key additions to its leadership team to strengthen its clinical and manufacturing operations. Dr. Harry Kochat takes on the role of Senior Director of Chemistry, Manufacturing and Controls, bringing over 30 years of experience in drug development and quality control. Darlene Bunpian joins as Clinical Trial Project Manager, overseeing the planned Phase 2 trial of LP-300 in Non-Small Cell Lung Cancer. The company aims to advance its oncology drug development utilizing its RADR® A.I. platform, while the new appointments are expected to enhance operational capabilities.
Lantern Pharma (LTRN) announced positive preclinical results for its drug candidate LP-184 against glioblastoma (GBM). The study showed LP-184 inhibits tumor growth by over 106% and extends survival in mice by 27% compared to controls. Conducted with Johns Hopkins, the findings support LP-184's potential in treating GBM, particularly in patients unresponsive to standard therapies. Lantern plans to refine dosing regimens and strengthen its FDA orphan drug application. This signifies a step towards addressing critical gaps in GBM treatment, benefiting patients with varying tumor profiles.
Lantern Pharma (LTRN) announced that its abstract, titled 'LP-184, a novel alkylating agent, is highly effective in pancreatic cancers with DNA damage repair defects', has been accepted for presentation at the AACR Virtual Special Conference on Pancreatic Cancer on September 29-30, 2021. The abstract highlights LP-184's promising efficacy in pancreatic cancer models, especially with DNA repair deficiencies. The drug has received Orphan Drug Designation from the FDA for pancreatic cancer treatment.
Lantern Pharma (LTRN) announced that the FDA has granted Orphan Drug Designation for its drug candidate LP-184, aimed at treating pancreatic cancer. This designation will provide seven years of market exclusivity, tax credits, and other benefits, enhancing the potential for LP-184's development. LP-184 has shown significant tumor shrinkage in preclinical models, highlighting its promise. The drug targets specific pancreatic cancer patients with certain biomarkers, potentially improving treatment outcomes in a cancer with a poor survival rate of 7.9% over five years.
Lantern Pharma (LTRN) reported its Q2 2021 financial results, highlighting significant advancements in its cancer therapy pipeline. The company aims to expedite drug development using its RADR® A.I. platform, with promising data from its LP-184 program targeting pancreatic cancer and other malignancies. Cash reserves surged to $79.6 million, aided by a $69 million public offering. However, R&D expenses increased to $1.16 million, contributing to a net loss of $2.32 million, or $0.21 per share. Upcoming milestones include clinical trials for LP-300 and data from collaborations with leading cancer research institutions.
Lantern Pharma (LTRN) announced an Asset Purchase Agreement to reacquire global development and commercialization rights for Irofulven (LP-100) from Allarity. This transaction also grants Lantern exclusive licensing to Allarity's companion diagnostic. The company is set to assume full control over LP-100's clinical development, which targets prostate and bladder cancer patients with ERCC2/3 gene mutations. Initial Phase 2 trial data showed a median overall survival of 12.5 months for treated patients. Lantern plans to expand its trials and aims for potential regulatory approvals in the US and EU.
Lantern Pharma (NASDAQ: LTRN) will host a conference call on July 29, 2021, at 4:30 p.m. ET to discuss its financial and operating results for Q2 2021, ending June 30, 2021. CEO Panna Sharma will lead the call with management team members. The call can be accessed via toll-free numbers and will be available for replay until August 29, 2021. Lantern Pharma is focused on oncology and utilizes its proprietary RADR® A.I. platform to enhance drug discovery and identify suitable patient profiles for its therapeutics.
Lantern Pharma (LTRN) announced promising preclinical data regarding its drug candidate, LP-184, in collaboration with the Fox Chase Cancer Center. The data showed over 90% tumor shrinkage in pancreatic cancer mouse models within 8 weeks, contrasting with significant tumor growth in untreated mice. The study also indicated that LP-184 is effective against various pancreatic cancer cell lines and patient-derived xenograft models, suggesting its potential for targeted therapy. Additionally, the research validated the role of PTGR1 in enhancing the drug's efficacy, supporting future trials aimed at genetically defined patient populations.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
